Literature DB >> 20560527

Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer.

Fred Bjørn Lih1, Mark A Titus, James L Mohler, Kenneth B Tomer.   

Abstract

Androgen deprivation therapy is the most common treatment option for advanced prostate cancer. Almost all prostate cancers recur during androgen deprivation therapy, and new evidence suggests that androgen receptor activation persists despite castrate levels of circulating androgens. Quantitation of tissue levels of androgens is critical to understanding the mechanism of recurrence of prostate cancer during androgen deprivation therapy. A liquid chromatography atmospheric pressure photoionization tandem mass spectrometric method was developed for quantitation of tissue levels of androgens. Quantitation of the saturated keto-steroids dihydrotestosterone and 5-alpha-androstanedione required detection of a novel parent ion, [M + 15](+). The nature of this parent ion was explored, and the method was applied to prostate tissue and cell culture with comparison to results achieved using electrospray ionization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560527      PMCID: PMC2928567          DOI: 10.1021/ac100460x

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  26 in total

Review 1.  Atmospheric pressure photoionization mass spectrometry.

Authors:  Andrea Raffaelli; Alessandro Saba
Journal:  Mass Spectrom Rev       Date:  2003 Sep-Oct       Impact factor: 10.946

2.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

3.  Atmospheric pressure photoionization: an ionization method for liquid chromatography-mass spectrometry

Authors: 
Journal:  Anal Chem       Date:  2000-08-01       Impact factor: 6.986

4.  Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry.

Authors:  Ming Zhao; Sharyn D Baker; Xiaohua Yan; Yiyu Zhao; William W Wright; Barry R Zirkin; Jonathan P Jarow
Journal:  Steroids       Date:  2004 Oct-Nov       Impact factor: 2.668

5.  Comparison of electrospray ionization and atmospheric pressure photoionization for coupling of micellar electrokinetic chromatography with ion trap mass spectrometry.

Authors:  Paul Hommerson; Amjad M Khan; Gerhardus J de Jong; Govert W Somsen
Journal:  J Chromatogr A       Date:  2008-04-15       Impact factor: 4.759

6.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

7.  PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Authors:  Steven A Kaplan; Claus G Roehrborn; Alan G Meehan; Kenneth S Liu; Alexandra D Carides; Bruce S Binkowitz; Norman L Heyden; E Darracott Vaughan
Journal:  Urology       Date:  2009-03-28       Impact factor: 2.649

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Sensitive simultaneous determination of ciclesonide, ciclesonide-M1-metabolite and fluticasone propionate in human serum by HPLC-MS/MS with APPI.

Authors:  Hermann J Mascher; Karl Zech; Daniel G Mascher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-05-16       Impact factor: 3.205

10.  Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.

Authors:  Ann W Hsing; Frank Z Stanczyk; Alain Bélanger; Paul Schroeder; Lilly Chang; Roni T Falk; Thomas R Fears
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

View more
  9 in total

1.  Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.

Authors:  John H Wilton; Mark A Titus; Eleni Efstathiou; Gerald J Fetterly; James L Mohler
Journal:  Prostate       Date:  2014-05       Impact factor: 4.104

2.  Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Authors:  James L Mohler; Mark A Titus; Elizabeth M Wilson
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

3.  5α-reductase type 3 enzyme in benign and malignant prostate.

Authors:  Mark A Titus; Yun Li; Olga G Kozyreva; Varun Maher; Alejandro Godoy; Gary J Smith; James L Mohler
Journal:  Prostate       Date:  2013-10-22       Impact factor: 4.104

Review 4.  A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer.

Authors:  James L Mohler
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

5.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

Review 6.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

7.  Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

Authors:  Mark A Titus; Brian Zeithaml; Boris Kantor; Xiangping Li; Karin Haack; Dominic T Moore; Elizabeth M Wilson; James L Mohler; Tal Kafri
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

8.  Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: A meta-analysis based on 20 publications.

Authors:  Cheng Fang; Zhong-Qiang Guo; Xiao-Yan Chen; Tong-Zu Liu; Xian-Tao Zeng; Xing-Huan Wang
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 9.  Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.

Authors:  Michael V Fiandalo; John Wilton; James L Mohler
Journal:  Int J Biol Sci       Date:  2014-06-03       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.